Top

Published in:

Open Access 01-12-2021 | Research

Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood

Authors: Jihane Boustani, Elodie Lauret Marie Joseph, Etienne Martin, Salim Benhmida, Benoit Lecoester, Florent Tochet, Céline Mirjolet, Cédric Chevalier, David Thibouw, Noémie Vulquin, Stéphanie Servagi, Xushan Sun, Olivier Adotévi

Published in: BMC Immunology | Issue 1/2021

Abstract

Background

The synergistic effect of chemoradiation (CRT) has been previously demonstrated in several cancer types. Here, we investigated the systemic immune effects of CRT in patients with lung or head and neck cancer.

Materials and methods

Peripheral blood mononuclear cells were collected at baseline and 1 month after treatment from blood samples of 29 patients treated with cisplatin-based chemoradiotherapy for lung or head and neck cancer. Circulating anti-tumor Th1 response was assessed by the ELISpot assay using a mixture of human leucocyte antigen (HLA) class II restricted peptides derived from telomerase (TERT). Phenotyping of circulating immunosuppressive cells (Treg and MDSC) was performed by flow cytometry.

Results

A significant increase of circulating Treg was observed in 60% of patients after CRT The mean rate of Treg was 3.1% versus 4.9% at baseline and after CRT respectively, p = 0.0015). However, there was a no significant increase of MDSC rate after CRT. In contrast, a decrease of tumor-specific Th1 response was documented in 7 out of 10 evaluated patients. We found high frequency of pre-existing tumor-specific Th1 response among patients with objective response after CRT compared to non-responders.

Conclusion

Cisplatin-based CRT promotes expansion of Treg and decrease of circulating anti-tumor Th1 response in peripheral blood. The balance towards a sustained specific anti-tumor T-cell response appears to be associated with response to CRT.

Available only for authorised users

Lawrence TS, Haffty BG, Harris JR. Milestones in the use of combined-modality radiation therapy and chemotherapy. J Clin Oncol. 2014;32(12):1173–9. https://doi.org/10.1200/JCO.2014.55.2281.CrossRefPubMed

Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256–65. https://doi.org/10.1093/jnci/djs629.CrossRefPubMed

Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009;10(7):718–26. https://doi.org/10.1016/S1470-2045(09)70082-8.CrossRefPubMedPubMedCentral

Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013;39(1):74–88. https://doi.org/10.1016/j.immuni.2013.06.014.CrossRefPubMed

Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001;106(3):255–8. https://doi.org/10.1016/S0092-8674(01)00449-4.CrossRefPubMed

Baba K, Nomura M, Ohashi S, Hiratsuka T, Nakai Y, Saito T, et al. Experimental model for the irradiation-mediated abscopal effect and factors influencing this effect. Am J Cancer Res. 2020;10(2):440–53.PubMedPubMedCentral

Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015;4(11):e1046028. https://doi.org/10.1080/2162402X.2015.1046028.CrossRefPubMedPubMedCentral

Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58(3):862–70. https://doi.org/10.1016/j.ijrobp.2003.09.012.CrossRefPubMed

Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in Cancer immunotherapy. JAMA Oncol. 2015;1(9):1325–32. https://doi.org/10.1001/jamaoncol.2015.2756.CrossRefPubMed

10.

Xu J, Escamilla J, Mok S, David J, Priceman S, West B, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013;73(9):2782–94. https://doi.org/10.1158/0008-5472.CAN-12-3981.CrossRefPubMedPubMedCentral

11.

Tsai C-S, Chen F-H, Wang C-C, Huang HL, Jung SM, Wu CJ, et al. Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int J Radiat Oncol Biol Phys. 2007;68(2):499–507. https://doi.org/10.1016/j.ijrobp.2007.01.041.CrossRefPubMed

12.

Chiang C-S, Fu SY, Wang S-C, Yu CF, Chen FH, Lin CM, et al. Irradiation promotes an m2 macrophage phenotype in tumor hypoxia. Front Oncol. 2012;2:89. https://doi.org/10.3389/fonc.2012.00089.CrossRefPubMed

13.

Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800. https://doi.org/10.1038/nm730.CrossRefPubMed

14.

Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48–57. https://doi.org/10.1038/ni.1674.CrossRefPubMed

15.

Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, et al. TIGIT and PD-1 mark Intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma. Cancer Immunol Res. 2019;7(3):355–62. https://doi.org/10.1158/2326-6066.CIR-18-0351.CrossRefPubMedPubMedCentral

16.

Grapin M, Richard C, Limagne E, Boidot R, Morgand V, Bertaut A, et al. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. J Immunother Cancer. 2019;7(1):160. https://doi.org/10.1186/s40425-019-0634-9.CrossRefPubMedPubMedCentral

17.

Schaue D, Xie MW, Ratikan JA, McBride WH. Regulatory T cells in radiotherapeutic responses. Front Oncol. 2012;2:90. https://doi.org/10.3389/fonc.2012.00090.CrossRefPubMed

18.

Shinto E, Hase K, Hashiguchi Y, Sekizawa A, Ueno H, Shikina A, et al. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer. Ann Surg Oncol. 2014;21(Suppl 3):S414–21. https://doi.org/10.1245/s10434-014-3584-y.CrossRefPubMed

19.

Homma Y, Taniguchi K, Murakami T, Nakagawa K, Nakazawa M, Matsuyama R, et al. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2014;21(2):670–6. https://doi.org/10.1245/s10434-013-3390-y.CrossRefPubMed

20.

Bhalla N, Brooker R, Brada M. Combining immunotherapy and radiotherapy in lung cancer. J Thorac Dis. 2018;1(1):S1447–60.CrossRef

21.

Demaria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol. 2012;2:153. https://doi.org/10.3389/fonc.2012.00153.CrossRefPubMed

22.

Demaria S, Pilones KA, Vanpouille-Box C, Golden EB, Formenti SC. The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. Radiat Res. 2014;182(2):170–81. https://doi.org/10.1667/RR13500.1.CrossRefPubMedPubMedCentral

23.

Kim H-J, Cantor H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res. 2014;2(2):91–8. https://doi.org/10.1158/2326-6066.CIR-13-0216.CrossRefPubMed

24.

Horna P, Cuenca A, Cheng F, Brayer J, Wang HW, Borrello I, et al. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood. 2006;107(7):2871–8. https://doi.org/10.1182/blood-2005-07-3014.CrossRefPubMed

25.

Braumüller H, Wieder T, Brenner E, Aßmann S, Hahn M, Alkhaled M, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature. 2013;494(7437):361–5. https://doi.org/10.1038/nature11824.CrossRefPubMed

26.

Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol Baltim Md 1950. 1998;161(5):2195–200.

27.

Lundin KU, Screpanti V, Omholt H, Hofgaard PO, Yagita H, Grandien A, et al. CD4+ T cells kill id+ B-lymphoma cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo. Cancer Immunol Immunother CII. 2004;53(12):1135–45. https://doi.org/10.1007/s00262-004-0538-4.CrossRefPubMed

28.

Southwood S, Sidney J, Kondo A, et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol Baltim Md 1950. 1998;160(7):3363–73.

29.

Consogno G, Manici S, Facchinetti V, Bachi A, Hammer J, Conti-Fine BM, et al. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood. 2003;101(3):1038–44. https://doi.org/10.1182/blood-2002-03-0933.CrossRefPubMed

30.

Wang X-F, Kerzerho J, Adotevi O, et al. Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients. J Immunol Baltim Md 1950. 2008;181(1):431–9. https://doi.org/10.4049/jimmunol.181.1.431.CrossRef

31.

Kim NW. Clinical implications of telomerase in cancer. Eur J Cancer Oxf Engl 1990. 1997;33(5):781–6. https://doi.org/10.1016/S0959-8049(97)00057-9.CrossRef

32.

Hannen R, Bartsch JW. Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis. FEBS Lett. 2018;592(12):2023–31. https://doi.org/10.1002/1873-3468.13084.CrossRefPubMed

33.

Laheurte C, Dosset M, Vernerey D, Boullerot L, Gaugler B, Gravelin E, et al. Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer. Br J Cancer. 2019;121(5):405–16. https://doi.org/10.1038/s41416-019-0531-5.CrossRefPubMed

34.

Beziaud L, Mansi L, Ravel P, Marie-Joseph EL, Laheurte C, Rangan L, et al. Rapalogs efficacy relies on the modulation of antitumor T-cell immunity. Cancer Res. 2016;76(14):4100–12. https://doi.org/10.1158/0008-5472.CAN-15-2452.CrossRefPubMed

35.

Spehner L, Kim S, Vienot A, et al. Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials. Int J Mol Sci. 2020;21(18). https://doi.org/10.3390/ijms21186838.

36.

Laheurte C, Galaine J, Beziaud L, et al. Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4+ Th1 responses against telomerase in cancer patients. Oncoimmunology. 2016;5(5). https://doi.org/10.1080/2162402X.2015.1137416.

37.

Kim S, François E, André T, Samalin E, Jary M, el Hajbi F, et al. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2018;19(8):1094–106. https://doi.org/10.1016/S1470-2045(18)30321-8.CrossRefPubMed

38.

Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, et al. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18(10):2943–53. https://doi.org/10.1158/1078-0432.CCR-11-3185.CrossRef

39.

Pignon J-P, le Maître A, Maillard E, Bourhis J. MACH-NC collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2009;92(1):4–14. https://doi.org/10.1016/j.radonc.2009.04.014.CrossRef

40.

Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116–25. https://doi.org/10.1016/S1470-2045(17)30318-2.CrossRefPubMedPubMedCentral

41.

Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 2017;8(1):1–20. https://doi.org/10.5306/wjco.v8.i1.1.CrossRefPubMed

42.

Hiyama E, Hiyama K. Telomerase as tumor marker. Cancer Lett. 2003;194(2):221–33. https://doi.org/10.1016/S0304-3835(02)00709-7.CrossRefPubMed

43.

Masterson L, Lechner M, Loewenbein S, et al. CD8+ T cell response to human papillomavirus 16 E7 is able to predict survival outcome in oropharyngeal cancer. Eur J Cancer Oxf Engl 1990. 2016;67:141–51. https://doi.org/10.1016/j.ejca.2016.08.012.CrossRef

44.

Schuler PJ, Harasymczuk M, Schilling B, Saze Z, Strauss L, Lang S, et al. Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(23):6585–96. https://doi.org/10.1158/1078-0432.CCR-13-0900.CrossRef

45.

Hanoteau A, Newton JM, Krupar R, Huang C, Liu HC, Gaspero A, et al. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy. J Immunother Cancer. 2019;7(1):10. https://doi.org/10.1186/s40425-018-0485-9.CrossRefPubMedPubMedCentral

46.

van Meir H, Nout RA, Welters MJP, Loof NM, de Kam ML, van Ham JJ, et al. Impact of (chemo) radiotherapy on immune cell composition and function in cervical cancer patients. Oncoimmunology. 2017;6(2):e1267095. https://doi.org/10.1080/2162402X.2016.1267095.CrossRefPubMed

47.

Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman J, Pecorelli S, et al. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int J Radiat Oncol Biol Phys. 2000;48(4):997–1006. https://doi.org/10.1016/s0360-3016(00)00769-0.CrossRefPubMed

48.

de Biasi AR, Villena-Vargas J, Adusumilli PS. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(21):5384–91. https://doi.org/10.1158/1078-0432.CCR-14-1298.CrossRef

49.

Galluzzi L, Zitvogel L, Kroemer G. Immunological mechanisms underneath the efficacy of Cancer therapy. Cancer Immunol Res. 2016;4(11):895–902. https://doi.org/10.1158/2326-6066.CIR-16-0197.CrossRefPubMed

50.

Dosset M, Vauchy C, Beziaud L, Adotevi O, Godet Y. Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination. Oncoimmunology. 2013;2(3):e23430. https://doi.org/10.4161/onci.23430.CrossRefPubMedPubMedCentral

51.

Adotevi O, Pere H, Ravel P, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother Hagerstown Md 1997. 2010;33(9):991–8. https://doi.org/10.1097/CJI.0b013e3181f4c208.CrossRef

Title: Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood
Authors: Jihane Boustani
Elodie Lauret Marie Joseph
Etienne Martin
Salim Benhmida
Benoit Lecoester
Florent Tochet
Céline Mirjolet
Cédric Chevalier
David Thibouw
Noémie Vulquin
Stéphanie Servagi
Xushan Sun
Olivier Adotévi
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: BMC Immunology / Issue 1/2021
Electronic ISSN: 1471-2172
DOI: https://doi.org/10.1186/s12865-021-00429-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Intratumoral regulatory T cells from colon cancer patients comprise several activated effector populations

PI3Kδ inhibition prevents IL33, ILC2s and inflammatory eosinophils in persistent airway inflammation

Circular RNA circFADS2 is overexpressed in sepsis and suppresses LPS-induced lung cell apoptosis by inhibiting the maturation of miR-15a-5p

CD100 modulates cytotoxicity of CD8+ T cells in patients with acute myocardial infarction

Direct effects of mast cell proteases, tryptase and chymase, on bronchial epithelial integrity proteins and anti-viral responses

Clinical observations of bone marrow transfusion for promoting bone marrow reconstruction after chemotherapy for AIDS-related lymphoma

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials